Stock listing

LSE:0QNA Basilea Pharmaceutica AG Share Price

UK listing (LSE) of Basilea Pharmaceutica AG · home listing SIX Swiss:BSLN

Follow Basilea Pharmaceutica AG into a list and get an email when it puts out news.

Share price · LSE:0QNA

72.50 CHF +3.65 (+5.3%)

Close on Oct 27, 2026

Day range
71.00 – 73.60 CHFOct 27, 2026
Volume
990 sharesOct 27, 2026
Basilea Pharmaceutica AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:BSLN · Home72.20 CHF+3.30 (+4.8%)151,42672.9075.8070.4068.90Close on Oct 27, 2026
LSE:0QNA72.50 CHF+3.65 (+5.3%)99073.6073.6071.0068.85Close on Oct 27, 2026
OTC:BPMUF$76.25 USD0.00 (0.0%)—$76.25$76.25$76.25$76.25Close on Oct 27, 2026
Ticker
LSE:0QNA
Asset type
Stock
Exchange
LSE
Currency
CHF

What changed lately

Calls

Replays

  • Basilea Pharmaceutica (SIX Swiss: BSLN) Q2 2026 Earnings Call

    Tue, Aug 18, 2026 · 10:00 AM ET

    Watch Transcript

Latest news

Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs

Oct 27, 2026

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Oct 20, 2026

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Sep 14, 2026

Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track

Aug 18, 2026

Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Aug 5, 2026

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Jul 29, 2026

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

May 28, 2026

Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

Apr 15, 2026

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Apr 9, 2026

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Mar 23, 2026

All Basilea Pharmaceutica AG news

Decks

Basilea Pharmaceutica AG on 6ix

News releases
20 in the last 12 months · 32 in all · newest Oct 27, 2026 · oldest 2025
Calls
1 call with a replay · 1 with a transcript · latest Aug 18, 2026
Decks
5 decks · latest Oct 27, 2026

Where Basilea Pharmaceutica AG is listed

ListingExchangeCountryCurrency
SIX Swiss:BSLN · Home listingSIX SwissSwitzerlandCHF
LSE:0QNA · This pageLSEUnited KingdomCHF
gettex:PK5gettexGermanyEUR
Aquis:BSLNZAquisUnited KingdomCHF
OTC:BPMUFOTCUnited StatesUSD
Lang & Schwarz:A0B9GALang & SchwarzGermanyEUR
LS Exchange:A0B9GALS ExchangeGermanyEUR
Tradegate:PK5TradegateGermanyEUR
BX Swiss:PK5BX SwissSwitzerlandCHF
Munich:PK5MunichGermanyEUR
Turquoise:BSLNZTurquoiseUnited KingdomCHF
Dusseldorf:PK5DusseldorfGermanyEUR
Frankfurt:PK5FrankfurtGermanyEUR
Hamburg:PK5HamburgGermanyEUR
Stuttgart:PK5StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Basilea Pharmaceutica AG.